Metronidazole

Introduction Overview

Generic Name

metronidazole

Brand Name

Flagyl

Dosage Form

oral tablets, extended-release tablets, oral suspension (liquid), intravenous injection

Drug Class

Amebicides, Miscellaneous antibiotics

Pharmacokinetics

Absorption:
Metronidazole is rapidly absorbed after oral administration with peak plasma concentrations reached within 20 minutes to 3 hours, depending on the formulation. Its bioavailability is nearly 100%, indicating efficient absorption from the gastrointestinal tract. Extended-release formulations provide a slower, more sustained absorption leading to prolonged systemic levels. Food intake does not significantly affect the extent of absorption but may slightly delay peak concentrations. Rapid and reliable absorption allows metronidazole to achieve therapeutic blood levels quickly, instrumental for acute infections.

Distribution:
Metronidazole exhibits wide distribution throughout body tissues and fluids, including the vaginal secretions, liver, lungs, brain, and cerebrospinal fluid, reflecting its effectiveness in treating infections in diverse anatomic locations including brain or spinal infections. Plasma protein binding is low, approximately 10–20%, allowing free drug availability. The drug crosses the blood-brain barrier and placenta, which necessitates caution during pregnancy. It also distributes into breast milk, and it is advised to avoid breastfeeding for 24 hours after administration due to potential exposure.

Metabolism:
Metronidazole undergoes extensive hepatic metabolism primarily by oxidation and glucuronidation into inactive metabolites. Cytochrome P450 enzymes such as CYP3A4 may be involved in biotransformation, though the primary metabolic pathways are phase II reactions. Metabolic activity may be altered in patients with liver impairment, potentially increasing plasma concentrations and toxicity risk. The drug’s half-life may be prolonged in such populations necessitating dose adjustments.

Elimination:
The renal route is the principal pathway for excretion of metronidazole and its metabolites, with approximately 60-80% eliminated in urine. Fecal excretion accounts for a minor extent. The elimination half-life in healthy adults ranges from 6 to 8 hours, supporting dosing regimens of two to three times daily. In patients with renal dysfunction, accumulation of metabolites can occur but does not significantly affect the parent compound elimination. Dose adjustments may be required in severe hepatic or renal insufficiency to prevent toxicity.

Dosage Forms

Available Dosage Forms:
- Oral tablets: Immediate-release tablets in 250 mg and 500 mg strengths
- Extended-release tablets: 750 mg strength, designed for sustained systemic release
- Oral suspension (liquid): Typically supplied with specific measuring devices for accurate dosing
- Intravenous (IV) injection and infusion: For parenteral use when oral administration is not feasible
- Oral capsules: Including 375 mg formulations

Dosages for Adults and Adolescents:
Flagyl dosing depends on the infection type and severity. Common regimens include 250-500 mg orally every 8 hours or 500 mg every 12 hours for most infections, administered for 7 to 10 days. The extended-release 750 mg tablet is typically given twice daily. For treatment of trichomoniasis, a single 2 g dose or 500 mg twice daily for 7 days are commonly used. In severe systemic infections, IV dosages range from 500 mg every 6 to 8 hours. Duration varies based on clinical response, commonly up to 10 days.

Specific Patient Populations:
In patients with hepatic impairment, dose reduction and careful monitoring are advised due to reduced metabolic clearance. Renal impairment generally does not necessitate dosage adjustment unless severe. Metronidazole is contraindicated during the first trimester of pregnancy for trichomoniasis due to potential fetal harm; however, it may be used cautiously in later trimesters. The drug is not approved for vaginal infections in premenarchal females. Use in children is guided by weight-based dosing, and safety in neonates requires close monitoring.

Clinical guidelines emphasize adherence to full treatment courses to prevent resistance and infection recurrence. Shaking oral suspensions well before administration ensures dose consistency. Extended-release tablets should be swallowed whole without crushing or chewing to preserve pharmacokinetic properties.

Mechanism Of Action

Metronidazole exerts its antimicrobial effects primarily through selective toxicity targeting anaerobic bacteria and protozoa. It is a prodrug that, upon entering susceptible organisms, undergoes enzymatic reduction of its nitro group by redox proteins found in anaerobic microbial cells, such as ferredoxin-like electron transport proteins. This reduction generates reactive nitro radical anions.

These nitro radical anions interact directly with microbial DNA causing strand breaks, loss of helical structure, and inhibition of nucleic acid synthesis, ultimately leading to cell death. The disruption of DNA synthesis effectively prevents replication, transcription, and repair processes in the target organisms. This mechanism accounts for its bactericidal and protozoacidal properties.

At the cellular level, metronidazole's activation is dependent on the anaerobic environment of target pathogens, as oxygen presence can reverse the drug's activated state, rendering aerobic organisms resistant. Unlike many antibiotics that target specific enzymes or cell wall synthesis, metronidazole's reductive activation and subsequent DNA damage is unique and effective against a broad spectrum of anaerobic pathogens.

Clinically, this unique mechanism allows metronidazole to be effective in treating infections where anaerobes predominate, such as bacterial vaginosis, amebiasis, trichomoniasis, and anaerobic abscesses. Its activity does not extend to aerobic bacteria or viruses, limiting its use to specific infection types. Compared to other antibiotics, metronidazole is favored for its potency against protozoal parasites and anaerobic bacteria and for its relatively low incidence of resistance. Research continually elucidates details of the reductive activation pathway, enhancing understanding of resistance mechanisms and informing structure-activity relationships for related compounds.

Pharmacological Actions

Acts as a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa
Exhibits bactericidal and protozoacidal activity by inducing DNA strand breakage
Inhibits nucleic acid synthesis resulting in cell death of susceptible organisms
Effective treatment for infections caused by Trichomonas vaginalis, Giardia lamblia, and Entamoeba histolytica
Used for anaerobic bacterial infections such as bacterial vaginosis, intra-abdominal abscesses, and periodontal infections
Crosses blood-brain barrier and achieves therapeutic levels in cerebrospinal fluid
Demonstrates anti-inflammatory properties by modulating neutrophil-mediated responses
Possesses activity selective for anaerobic environments due to requirement for reduction under low oxygen
Metabolized in liver to inactive derivatives with relatively low plasma protein binding
Exhibits relatively low potential for bacterial resistance development when used appropriately
May have synergistic effects when combined with other antimicrobials, broadening clinical utility
Exerts some cytotoxic effects in vitro, underlying concerns regarding carcinogenic potential in animal studies
Displays disulfiram-like reaction when combined with alcohol due to inhibition of aldehyde dehydrogenase
Can modulate intestinal flora and cause secondary fungal overgrowth due to broad-spectrum microbicidal action

Therapeutic Or Clinical Uses

Treatment of bacterial infections in the vagina, including bacterial vaginosis
Management of gastrointestinal infections such as amebiasis and giardiasis
Treatment of trichomoniasis, a sexually transmitted protozoal infection
Therapy for skin, soft tissue, and joint infections caused by anaerobic bacteria
Treatment of central nervous system infections including brain abscesses and bacterial meningitis involving anaerobes
Use in respiratory infections like aspiration pneumonia linked to anaerobic pathogens
Management of bloodstream infections (bacteremia) due to susceptible anaerobic bacteria
Preoperative and postoperative prophylaxis in surgeries prone to anaerobic infection
Use in pelvic inflammatory disease and endocarditis involving anaerobic pathogens
Treatment of intra-abdominal abscesses and peritonitis
Adjunctive therapy in Helicobacter pylori eradication regimens
Treatment of clostridial infections including Clostridium difficile-associated diarrhea (off-label)
Topical and systemic therapy for periodontal infections
Treatment of certain protozoal infections and parasitic infestations in veterinary medicine
Eradication of resistant anaerobic components in mixed infections when combined with other antibiotics

Side Or Adverse Effects

Gastrointestinal disturbances including nausea, vomiting, abdominal pain, diarrhea, and constipation
Unpleasant metallic taste in the mouth, often persistent throughout therapy
Headache, dizziness, and weakness reported frequently during treatment
Central nervous system effects including seizures, confusion, peripheral neuropathy such as numbness and tingling
Allergic reactions ranging from rash and itching to severe hypersensitivity and anaphylaxis
Neurological symptoms such as ataxia, vision disturbances, and optic neuropathy, especially with long-term use
Vaginal itching or discharge and pain during sexual intercourse related to yeast superinfection
Oral mucosal changes including sores, stomatitis, and a swollen or hairy tongue
Rare but serious hepatotoxicity including potential for liver failure, especially in susceptible individuals
Disulfiram-like reaction with alcohol ingestion leading to flushing, tachycardia, nausea, and vomiting
Potential carcinogenicity suggested from animal studies, though human risk remains unclear
Fungal superinfections due to disruption of normal microbial flora
Transient darkening of urine to reddish-brown color, which is benign
Possible cardiovascular effects including palpitations and arrhythmias in rare cases
Exacerbation of pre-existing blood dyscrasias or development of leukopenia and anemia

Precautions

Avoid alcohol consumption or any products containing alcohol or propylene glycol during and for at least 3 days after treatment
Use with caution in patients with liver impairment due to altered metabolism and increased toxicity risk
Monitor neurologic status closely during long-term therapy to detect early signs of peripheral neuropathy or CNS effects
Not recommended during the first trimester of pregnancy, particularly for treatment of trichomoniasis
Avoid breastfeeding for at least 24 hours after dosing due to drug excretion in breast milk
Use caution in patients with a history of blood dyscrasias or anemia
Discontinue therapy immediately if signs of severe allergic reaction or Stevens-Johnson syndrome appear
Evaluate renal function in patients receiving prolonged therapy
Avoid use in patients who have recently taken disulfiram due to risk of neurotoxicity
Inform healthcare providers of metronidazole use prior to diagnostic testing due to possible interference
Use carefully in elderly patients as they may be more susceptible to adverse effects
Consider alternative therapy if patient has known hypersensitivity to nitroimidazoles
Avoid concurrent use with other neurotoxic drugs when possible to reduce additive CNS toxicity
Educate patients regarding the importance of completing the full course even if symptoms improve
Use caution in patients with central nervous system disorders or history of seizures

Warnings

Contraindicated in patients who have consumed alcohol or propylene glycol within 3 days prior to administration
Do not use in combination with disulfiram or within 2 weeks after disulfiram treatment due to risk of severe neurologic events
Potential for serious neurologic adverse reactions including seizures, encephalopathy, and peripheral neuropathy
May cause severe hypersensitivity and life-threatening skin reactions such as Stevens-Johnson syndrome
Animal studies indicate carcinogenic potential, but human risk remains undefined — use only if clearly needed
The drug is ineffective for viral infections and should not be used to treat colds or flu
Caution in patients with Cockayne syndrome due to risk of life-threatening liver failure
Risk of yeast infections secondary to alterations in normal flora during therapy
Use in first trimester pregnancy for trichomoniasis is contraindicated due to potential teratogenicity
Serious hepatotoxicity and liver dysfunction reported in rare cases; monitor liver function tests
Inability to treat non-bacterial infections; consideration should be given to appropriate microbial diagnosis
Potential to alter results of certain laboratory tests, requiring communication with healthcare providers
Risk of overdose leading to CNS toxicity, including balance disorders and muscle weakness
Should not be used in pediatric vaginal infections in premenarchal girls
Avoid sharing the medication to prevent inappropriate use and resistance development

Contraindication

Known hypersensitivity to metronidazole, secnidazole, tinidazole, or other nitroimidazole derivatives
Recent consumption of alcohol or propylene glycol-containing products within 3 days prior to dosing
Treatment with disulfiram within the previous 14 days due to increased risk of toxicity
Use during the first trimester of pregnancy for treatment of trichomoniasis due to fetal risk
Use in premenarchal females for treatment of vaginal infections due to lack of safety data
Patients with a history of severe neurological disorders where drug-induced CNS toxicity is a concern
Patients with Cockayne syndrome due to risk of severe life-threatening liver toxicity
Concomitant use with disulfiram or other drugs causing disulfiram-like reactions
Severe hepatic failure without possibility of close monitoring and dose adjustments
Patients with active central nervous system diseases that may be exacerbated by metronidazole
Known blood dyscrasias where further risk of anemia or leukopenia is clinically significant
Hypersensitivity to any formulation components, including oral suspension excipients
Avoid use for viral infections such as influenza or common cold where the drug is ineffective
Patients unwilling or unable to comply with warnings regarding alcohol avoidance
History of severe allergic or skin reactions to nitroimidazole antibiotics

Drug Interactions

Concurrent use with warfarin or other anticoagulants can potentiate anticoagulant effect and increase bleeding risk
Potential interactions with antidepressants that may increase CNS adverse reactions or serotonin syndrome risk
Combination with lithium may elevate lithium levels leading to toxicity
Use with busulfan or other chemotherapeutic agents may alter drug metabolism and enhance toxicity
Concurrent use with antipsychotics may increase risk of neurotoxicity or CNS side effects
Interactions with antihypertensive medications could alter blood pressure control
Concomitant administration with antimalarial drugs demands careful monitoring for enhanced side effects
Drugs metabolized by hepatic CYP enzymes may have altered metabolism due to competition or inhibition
Potential interaction with HIV medications that may affect metronidazole levels or efficacy
Use with disulfiram is contraindicated due to severe neurotoxicity
Alcohol or propylene glycol ingestion during metronidazole therapy leads to a disulfiram-like reaction
May alter outcomes of certain laboratory tests, necessitating coordination with laboratory personnel
Use with other CNS depressants may potentiate central nervous system adverse effects
Possible pharmacokinetic interactions with other antibiotics, necessitating clinical monitoring
Over-the-counter supplements or herbal products may affect metabolism or increase side effects

Preparations Of The Drug

Flagyl Immediate-Release Oral Tablets in strengths of 250 mg, 500 mg
Flagyl Extended-Release Oral Tablets, 750 mg, providing sustained plasma levels
Flagyl Oral Suspension (liquid) with supplied measuring device for accurate dosing
Flagyl Intravenous Injection for parenteral administration in patients unable to swallow
Flagyl Oral Capsules, including 375 mg formulations
Generic metronidazole formulations available in various strengths and dosage forms
Likmez, alternate brand of oral metronidazole suspension
Flagyl ER, extended-release brand formulations for twice-daily dosing
Combination therapies available incorporating metronidazole with other antibiotics for specific indications
Topical and vaginal formulations of metronidazole for localized infections (not detailed in current data)
Standard packaging includes blister packs for tablets and bottles for suspensions
Parenteral formulations prepared as sterile solutions for intravenous infusion
Special pediatric formulations with adjusted concentration for weight-based dosing
Preservative-free options available in some preparations to reduce allergenic potential
Patient instructional materials provided with all preparations to ensure proper usage and adherence